4-(Chloromethyl)-5-methylisoxazole
![]() |
- $45 - $1796
- Product name: 4-(Chloromethyl)-5-methylisoxazole
- CAS: 104988-43-4
- MF: C5H6ClNO
- MW: 131.56
- EINECS:
- MDL Number:MFCD19232563
- Synonyms:4-(Chloromethyl)-5-methylisoxazole;4-(chloromethyl)-5-methyl-1,2-oxazole;Isoxazole, 4-(chloromethyl)-5-methyl-
4 prices
Selected condition:
Brand
- AK Scientific
- Chemenu
- Crysdot
- TRC
Package
- 10mg
- 1g
- 2.5g
- ManufacturerAK Scientific
- Product numberX3761
- Product description4-Chloromethyl-5-methyl-isoxazole
- Packaging2.5g
- Price$1796
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM191271
- Product description4-Chloromethyl-5-methyl-isoxazole 95%
- Packaging1g
- Price$464
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11359717
- Product description4-(Chloromethyl)-5-methylisoxazole 95+%
- Packaging1g
- Price$491
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB420568
- Product description4-(Chloromethyl)-5-methyl-1,2-oxazole
- Packaging10mg
- Price$45
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | X3761 | 4-Chloromethyl-5-methyl-isoxazole | 2.5g | $1796 | 2021-12-16 | Buy |
Chemenu | CM191271 | 4-Chloromethyl-5-methyl-isoxazole 95% | 1g | $464 | 2021-12-16 | Buy |
Crysdot | CD11359717 | 4-(Chloromethyl)-5-methylisoxazole 95+% | 1g | $491 | 2021-12-16 | Buy |
TRC | B420568 | 4-(Chloromethyl)-5-methyl-1,2-oxazole | 10mg | $45 | 2021-12-16 | Buy |
Properties
Boiling point :78 °C(Press: 6 Torr)
Density :1.2028 g/cm3
pka :-2.23±0.50(Predicted)
Density :1.2028 g/cm3
pka :-2.23±0.50(Predicted)
Safety Information
Symbol(GHS): |
![]() ![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|